Mean (SEM) | Linagliptin (n = 5758) | Active comparators (n = 918) | Placebo (n = 2618) | Total comparators (n = 3536) |
---|---|---|---|---|
Total cholesterol, mg/dL | Â | Â | Â | Â |
Baseline | 187 (0.6) | 186 (1.3) | 187 (0.9) | 187 (0.8) |
Change from baseline | 1 (0.5) | 2 (1.1) | 2 (0.7) | 2 (0.6) |
LDL, mg/dL | Â | Â | Â | Â |
Baseline | 107 (0.5) | 104 (1.1) | 107 (0.7) | 106 (0.6) |
Change from baseline | 1 (0.4) | 4 (0.9) | 1 (0.6) | 1 (0.5) |
HDL, mg/dL | Â | Â | Â | Â |
Baseline | 47 (0.2) | 48 (0.4) | 47 (0.3) | 47 (0.2) |
Change from baseline | 1 (0.1) | −1 (0.2) | 1 (0.2) | 1 (0.1) |
Triglyceride, mg/dL | Â | Â | Â | Â |
Baseline | 173 (1.8) | 180 (4.1) | 174 (2.9) | 176 (2.4) |
Change from baseline | −7 (1.5) | −8 (4.2) | −3 (2.6) | −5 (2.2) |
HbA1c, % | Â | Â | Â | Â |
Baseline | 8.1 (0.01) | 7.8 (0.03) | 8.3 (0.02) | 8.1 (0.02) |
Change from baseline | −0.7 (0.01) | −0.5 (0.03) | −0.3 (0.02)* | −0.3 (0.02) |
Weight | Â | Â | Â | Â |
Baseline | 79.5 (0.25) | 83.8 (0.58) | 81.1 (0.39) | 81.9 (0.32) |
Change from baseline | −0.1 (0.05) | 1.3 (0.15) | 0.1 (0.07) | 0.4 (0.06) |
Systolic BP (mmHg) | Â | Â | Â | Â |
Baseline | 131 (0.2) | 134 (0.5) | 132 (0.3) | 132 (0.3) |
Change from baseline | −1 (0.2) | −1 (0.5) | −1 (0.3) | −1 (0.3) |
Diastolic BP (mmHg) | Â | Â | Â | Â |
Baseline | 78 (0.1) | 80 (0.3) | 78 (0.2) | 79 (0.2) |
Change from baseline | −1 (0.1) | −1 (0.3) | −1 (0.2) | −1 (0.2) |
Heart rate, bpm | Â | Â | Â | Â |
Baseline | 74 (0.1) | 73 (0.4) | 74 (0.2) | 74 (0.2) |
Change from baseline | 1 (0.1) | −1 (0.3) | 1 (0.3) | 1 (0.2) |